Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Fibrobiologics maintains a patent portfolio within the Biotechnology & Pharmaceuticals technology area. The company currently has 2 pending office actions that require responses. These actions are distributed across 2 distinct examiners, which means the prosecution workload is shared between different individuals. Additionally, the portfolio is active within 2 distinct art units, indicating that the technical subject matter spans multiple specialized groups at the patent office.
The busiest examiner for this portfolio is ABEYRATNE-PERERA, HASHANTHI KOMITIGE, who is currently handling 1 busiest examiner pending office action. Since there are 2 pending office actions in total, this examiner is responsible for 1 of the active matters. Practitioners should be aware that with 2 distinct examiners and 2 distinct art units, the company must manage different examination styles and technical standards. The presence of 2 pending office actions across 2 distinct examiners suggests a need for a coordinated approach to ensure consistency in the company's intellectual property strategy within the Biotechnology & Pharmaceuticals sector.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ABEYRATNE-PERERA, HASHANTHI KOMITIGE | 1 | 0.0% | +0.0% |
| SMALL, KATHERINE R | 1 | 68.9% | +30.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17738584 | INDUCTION OF TUMOR VASCULAR NECROSIS UTILIZING FIBROBLASTS | SMALL, KATHERINE R | 107d overdue |
| 18483264 | PREPARATION AND THERAPEUTIC USE OF 3D-CULTURED FIBROBLASTS | ABEYRATNE-PERERA, HASHANTHI KOMITIGE | 4d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17738584 | INDUCTION OF TUMOR VASCULAR NECROSIS UTILIZING FIBROBLASTS | SMALL, KATHERINE R | 107d overdue |
| Art Unit | Apps |
|---|---|
| 1632 | 1 |
| 1633 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18483264 | PREPARATION AND THERAPEUTIC USE OF 3D-CULTURED FIBROBLASTS | ABEYRATNE-PERERA, HASHANTHI KOMITIGE | 1632 | §103 | Final Rejection | 4d overdue | Pending | Oct 09, 2023 |
| 17738584 | INDUCTION OF TUMOR VASCULAR NECROSIS UTILIZING FIBROBLASTS | SMALL, KATHERINE R | 1633 | §102§103§112 | Final Rejection | 107d overdue | Pending | May 06, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial